Source link : https://www.newshealth.biz/health-news/new-pd-1-inhibitor-approved-for-esophageal-cancer/
The FDA approved tislelizumab (Tevimbra) for advanced/metastatic esophageal squamous cell carcinoma (ESCC) previously treated with chemotherapy, BeiGene announced. The approval stipulates use of the PD-1 inhibitor in adults with advanced ESCC following systemic therapy that did not include a PD-1/L1 inhibitor. The action makes ESCC the first approved indication for tislelizumab in the U.S., according […]
Author : News Health
Publish date : 2024-03-15 09:55:52
Copyright for syndicated content belongs to the linked Source.
Categories